{"filings":[{"id":1618608,"accession_number":"0001185185-26-002922","cik":1326205,"company_name":"IGC Pharma, Inc.","ticker":"IGC","form_type":"8-K","filed_at":"2026-07-13T22:11:32+00:00","items":["7.01","9.01"],"status":"ready","headline":"IGC Pharma updates investor presentation: Phase 2 CALMA trial >80% enrolled, interim data show agitation reduction","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Phase 2 CALMA trial for IGC-AD1 in agitation in Alzheimer's: >80% of 146 target participants completed dosing.","Blinded pooled data (n=107) show LS mean CMAI change of -13.6 at week 2 and -14.9 at week 6 from baseline.","Interim analysis (n=26) showed IGC-AD1 numerically earlier and larger CMAI reduction vs published brexpiprazole data.","Sleep disturbance reduced 71% at week 2 (p=0.012) and 78% at EOT (p=0.02) in interim analysis.","Current market cap ~$30M; presentation outlines potential valuation inflection to $350M-$750M post positive Phase 2."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":28285807.226896554,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1471278,"accession_number":"0001185185-26-002808","cik":1326205,"company_name":"IGC Pharma, Inc.","ticker":"IGC","form_type":"8-K","filed_at":"2026-07-06T20:02:00+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"IGC Pharma issues 4.27M shares to CEO and PFO to cancel $1.15M in debt","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["CEO Ram Mukunda receives 2,226,475 shares for cancellation of $601,148 owed, including $283,639 in cash advances.","VP/PFO Claudia Grimaldi receives 2,048,378 shares for cancellation of $553,062 owed, including $268,723 in cash advances.","Total debt reduction of $1,154,210; no cash paid by the Company; equity increases by same amount.","Shares issued at $0.27 per share; transaction approved by independent directors and Audit Committee under Rule 16b-3.","Shares are restricted, unregistered, and issued under Section 4(a)(2) exemption; resale subject to securities laws."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":28285807.226896554,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":917997,"accession_number":"0001185185-26-002410","cik":1326205,"company_name":"IGC Pharma, Inc.","ticker":"IGC","form_type":"8-K","filed_at":"2026-06-08T20:03:16+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"IGC Pharma extends $12M loan agreement with O-Bank; facility fee rises to $60,000","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Entered amendment to extend Master Loan and Security Agreement with O-Bank Co., Ltd.","Facility maximum aggregate limit remains $12,000,000 unchanged from 2025.","Facility fee increased from $48,000 to $60,000; other terms substantially unchanged.","Loan agreement continues the general banking facility arrangement originally dated June 24, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":28285807.226896554,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":92140,"accession_number":"0001185185-26-001437","cik":1326205,"company_name":"IGC Pharma, Inc.","ticker":"IGC","form_type":"8-K","filed_at":"2026-04-20T23:59:59+00:00","items":["1.01","2.03","3.02","9.01"],"status":"ready","headline":"IGC Pharma raises $514K via two convertible promissory notes with OID","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["FirstFire note: $346,910 principal at $307K purchase price, OID $39,910, 12% interest, matures April 10, 2027.","Vanquish note: $238,050 principal at $207K purchase price, OID $31,050, 12% interest, matures March 30, 2027.","Upon default, holders can convert at 75% of lowest trading price over prior 10 days; 4.99% beneficial ownership cap per holder.","Conversion capped at 19.99% of outstanding shares without shareholder approval; proceeds for general working capital.","Notes are unregistered, issued as exempt under Section 4(a)(2) of the Securities Act."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":28285807.226896554,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":102748,"accession_number":"0001185185-26-001146","cik":1326205,"company_name":"IGC Pharma, Inc.","ticker":"IGC","form_type":"8-K","filed_at":"2026-03-30T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"IGC Pharma partners with New to The Street for 12-part national media campaign","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["12-part campaign includes TV interviews on Fox Business and Bloomberg Television.","Outdoor billboards in Times Square and NYC Financial District planned as part of promotion.","Digital amplification reaches over 4.45 million YouTube subscribers across platforms.","Partnership aims to boost investor awareness across institutional and retail audiences."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":28285807.226896554,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":102747,"accession_number":"0001185185-26-000846","cik":1326205,"company_name":"IGC Pharma, Inc.","ticker":"IGC","form_type":"8-K","filed_at":"2026-03-12T23:59:59+00:00","items":["1.01","2.03","3.02","9.01"],"status":"ready","headline":"IGC Pharma issues $353K convertible note to Vanquish Funding; also obtains $219K loan","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Principal $353,050 includes $46,050 original issue discount; net proceeds $307,000 for working capital.","Upon default, holder can convert at 75% of lowest 10-day trading price, subject to 4.99% ownership cap.","Additional tranche up to $2,015,000 over 12 months available subject to further agreement.","Separate loan from One Deck Capital of ~$219,000 with scheduled periodic payments for general corporate purposes.","Conversion capped at 19.99% of outstanding shares without shareholder approval per NYSE American rules."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":28285807.226896554,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":102746,"accession_number":"0001185185-26-000032","cik":1326205,"company_name":"IGC Pharma, Inc.","ticker":"IGC","form_type":"8-K","filed_at":"2026-01-06T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"IGC Pharma raises ~$234k in registered direct offering of 780k shares at $0.30/share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Issued 779,997 shares of common stock at $0.30 per share for gross proceeds of ~$234k.","Offering closed on or about January 5, 2026 under existing shelf registration statement.","Net proceeds to fund working capital, clinical development, R&D, and other business initiatives."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":28285807.226896554,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":102745,"accession_number":"0001185185-26-000010","cik":1326205,"company_name":"IGC Pharma, Inc.","ticker":"IGC","form_type":"8-K","filed_at":"2026-01-02T23:59:59+00:00","items":["5.03"],"status":"ready","headline":"IGC Pharma changes fiscal year-end from March 31 to December 31, effective 2025","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Board approved fiscal year change from March 31 to December 31, effective Dec 31, 2025.","Company will file a Transition Report on Form 10-K for the nine-month period April 1 to Dec 31, 2025.","Future fiscal years will end on December 31, aligning with the calendar year."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":28285807.226896554,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":118980,"accession_number":"0001185185-25-002055","cik":1326205,"company_name":"IGC Pharma, Inc.","ticker":"IGC","form_type":"8-K","filed_at":"2025-12-15T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"IGC Pharma increases authorized common stock from 150M to 600M shares","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Amendment effective Dec 12, 2025, after stockholder approval on Oct 10, 2025.","Authorized common stock raised from 150M to 600M shares; preferred stock unchanged at 1M shares.","Total authorized shares (all classes) increased from 151M to 601M shares."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":28285807.226896554,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":118979,"accession_number":"0001185185-25-001713","cik":1326205,"company_name":"IGC Pharma, Inc.","ticker":"IGC","form_type":"8-K","filed_at":"2025-11-14T23:59:59+00:00","items":["2.01","9.01"],"status":"ready","headline":"IGC Pharma closes sale of Vancouver facility assets for ~$2.7M in non-cash consideration","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Closed Nov 13, 2025; subsidiary Holi Hemp sold equipment, inventory, and leasehold assets to Wellness Essentials Northwest LLC.","Total fair value of consideration ~$2.7M, comprising preferential manufacturing rights through Dec 2030 and 10% contingent payment if buyer sells within 5 years.","Pro forma gain on disposal of $1.05M recognized; intangible asset of $2.7M recorded for supply contract.","No cash received; deal secures manufacturing capacity at preferential pricing starting 2028.","Pro forma balance sheet shows total assets of $8.99M and stockholders' equity of $7.13M as of June 30, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":28285807.226896554,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":118978,"accession_number":"0001185185-25-001428","cik":1326205,"company_name":"IGC Pharma, Inc.","ticker":"IGC","form_type":"8-K","filed_at":"2025-10-14T23:59:59+00:00","items":["5.07","8.01","9.01"],"status":"ready","headline":"IGC Pharma shareholders approve 4x increase in authorized shares to 600M and 5M share grant","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Shareholders approved amendment to increase authorized common stock from 150M to 600M shares.","Approved grant of up to 5M shares for employees, advisors, directors, and consultants under performance metrics.","Re-elected directors Ram Mukunda and James Moran as Class C directors until 2028.","Ratified Manohar Chowdhry & Associates as independent auditor for fiscal 2026.","Non-binding advisory vote set frequency of executive compensation votes every three years."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":28285807.226896554,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":118977,"accession_number":"0001185185-25-001326","cik":1326205,"company_name":"IGC Pharma, Inc.","ticker":"IGC","form_type":"8-K","filed_at":"2025-10-01T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"IGC Pharma subsidiary sells assets and facility to Wellness Essentials for ~$2.7M","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Holi Hemp sold equipment, inventory, and Vancouver ready-to-move facility to Wellness Essentials Northwest.","Fair value of ~$2.7M, subject to auditor valuation review and board approvals as closing conditions.","Buyer assumes employee, utility, and lease obligations; HHP pays health insurance through Nov 30, 2025.","Seller gets preferential supply rights with 20% min margin plus 10-20% additional margins for 2028-2030.","If Buyer sells operating business within 5 years, Seller receives 10% of net proceeds."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":28285807.226896554,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":152511,"accession_number":"0001185185-25-000657","cik":1326205,"company_name":"IGC Pharma, Inc.","ticker":"IGC","form_type":"8-K","filed_at":"2025-06-17T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"IGC Pharma Phase 2 CALMA trial shows significant agitation reduction in Alzheimer's patients","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Phase 2 interim: CMAI total score improvement -10.46 at week 6 (p=0.042, Cohen d=0.79) vs placebo.","Sleep disturbance improved 71% at week 2 (p=0.012) and 78% at week 6 (p=0.02) on NPI-12 sleep subdomain.","Phase 1 (n=13): no SAEs; agitation reduced significantly across all doses (p<0.05 each) on NPI agitation domain.","Genotype-dependent PK: intermediate CYP2C9 metabolizers had longer IGC-AD1 half-life, potential for personalized dosing.","Phase 2 CALMA trial targeting full enrollment of 146 participants for agitation in Alzheimer's dementia."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":28285807.226896554,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":204798,"accession_number":"0001185185-24-000923","cik":1326205,"company_name":"IGC Pharma, Inc.","ticker":"IGC","form_type":"8-K","filed_at":"2024-09-27T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"IGC Pharma sells 588,235 shares to director-owned entity for $200,000 at $0.34 each","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Shares issued to Moran Global Strategies, owned by director James Moran, at $0.34/share.","Total proceeds of $200,000; closing subject to NYSE American approval.","Outstanding shares post-closing will be ~75,953,296; no warrants or options outstanding.","Investor receives piggyback registration rights with expense cap of $2,500.","Shares issued under Section 4(a)(2) exemption from registration."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":28285807.226896554,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":204797,"accession_number":"0001185185-24-000851","cik":1326205,"company_name":"IGC Pharma, Inc.","ticker":"IGC","form_type":"8-K","filed_at":"2024-08-27T23:59:59+00:00","items":["5.07","8.01","9.01"],"status":"ready","headline":"IGC Pharma stockholders re-elect two directors, ratify auditor, approve 5M share grant","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Richard Prins (26,116,740 for) and Terry Lierman (27,800,503 for) re-elected as Class B directors until 2027.","Ratified Manohar Chowdhry & Associates as independent registered public accounting firm for 2025 fiscal year (42,587,128 for).","Approved grant of up to 5,000,000 common shares to employees, advisors, directors, and consultants.","Non-binding advisory vote indicates executive compensation votes will be held every three years.","Approximately 56.6% of outstanding shares (42,811,367) voted; 14,877,728 broker non-votes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":28285807.226896554,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":204796,"accession_number":"0001185185-24-000755","cik":1326205,"company_name":"IGC Pharma, Inc.","ticker":"IGC","form_type":"8-K","filed_at":"2024-08-02T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"IGC Pharma extends loan agreement with O-Bank; facility fees cut to $84,000 from $120,000","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Extension effective July 8, 2024, extends term of existing Master Loan and Security Agreement under same terms.","Facility fees reduced to $84,000 from $120,000; no other material changes to the agreement.","The loan agreement was previously disclosed in July 2023 8-K; this amendment solely extends the term.","No new borrowing or change in principal amount; obligation remains under existing credit facility."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":28285807.226896554,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":221644,"accession_number":"0001185185-24-000360","cik":1326205,"company_name":"IGC Pharma, Inc.","ticker":"IGC","form_type":"8-K","filed_at":"2024-04-05T23:59:59+00:00","items":["7.01","9.01","8.01"],"status":"ready","headline":"IGC Pharma reports positive interim Phase 2 results for IGC-AD1 in Alzheimer's agitation","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Cohen's d effect size at week 6=0.66, CMAI LS mean difference vs placebo=-10.45, p=0.037.","At pre-specified week 2 endpoint, effect size=0.79, suggesting early onset of action.","Interim results compare favorably to Brexpiprazole's Phase 3 (Cohen's d 0.35, LS mean -5.32).","Trial ongoing (n=26 interim); final results may differ as enrollment continues in US and Canada.","IGC-AD1 targets CB1 receptor, neuroinflammation, and inflammasome-3 pathways."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":28285807.226896554,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":241197,"accession_number":"0001185185-24-000324","cik":1326205,"company_name":"IGC Pharma, Inc.","ticker":"IGC","form_type":"8-K","filed_at":"2024-03-28T23:59:59+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"IGC Pharma announces $3M private placement with Bradbury Asset Management at $0.34/share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Issued 8,823,529 unregistered common shares at $0.34/share to Bradbury Asset Management on March 22, 2024.","Gross proceeds of $3 million to fund general corporate purposes and advance investigational drug IGC-AD1.","Closing subject to customary conditions including NYSE approval; shares not immediately tradable.","After issuance, IGC will have ~75,365,061 shares outstanding; piggyback registration rights granted."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":28285807.226896554,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":241196,"accession_number":"0001185185-24-000301","cik":1326205,"company_name":"IGC Pharma, Inc.","ticker":"IGC","form_type":"8-K","filed_at":"2024-03-22T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"IGC Pharma enters ATM sales agreement for up to $60M in common stock","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Agreement with A.G.P./Alliance Global Partners allows at-the-market sales of up to $60 million in common stock.","Board initially reserved 171,428,571 shares based on $0.35 reference price; commission set at 3.0% of gross proceeds.","Sales may occur from time to time via NYSE American; agent not obligated to purchase shares on principal basis.","Annual maintenance fee of $10,000 payable to sales agent; agreement terminates after three years or earlier by notice."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":28285807.226896554,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":241195,"accession_number":"0001185185-24-000233","cik":1326205,"company_name":"IGC Pharma, Inc.","ticker":"IGC","form_type":"8-K","filed_at":"2024-03-13T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"IGC Pharma appoints Terry Lierman as independent director to advance Alzheimer's pipeline","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Terry Lierman appointed as independent Class B director, effective March 12, 2024.","Lierman brings healthcare leadership: co-chair IHV, founder of Children's Research Institute, PanCAN, NOFAS.","Granted options to buy 150,000 shares at $0.30/share; 50,000 vest immediately, balance over 2025-2026.","His expertise will support Phase 2 trial of IGC-AD1 for agitation in Alzheimer's and preclinical TGR-63.","CEO Ram Mukunda cites Lierman's strategic guidance as pivotal for pipeline advancement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":28285807.226896554,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":258660,"accession_number":"0001185185-23-001111","cik":1326205,"company_name":"IGC Pharma, Inc.","ticker":"IGC","form_type":"8-K","filed_at":"2023-10-27T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"IGC Pharma enters $60M ATM equity offering with A.G.P./Alliance Global Partners","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["On Oct 27, 2023, IGC Pharma entered an ATM sales agreement with A.G.P./Alliance Global Partners to sell up to $60M of common stock.","A.G.P. will receive a 3% commission on gross proceeds; the company reimburses up to $40K legal fees and $10K annual maintenance.","The prior ATM agreement with The Benchmark Company (Jan 2021) was terminated.","Board initially reserved shares based on Oct 25 closing price of $0.29 per share.","Agreement terminates upon sale of all shares, or by either party with 5 days' notice, or registration statement expiry."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":28285807.226896554,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":275966,"accession_number":"0001185185-23-000887","cik":1326205,"company_name":"IGC Pharma, Inc.","ticker":"IGC","form_type":"8-K","filed_at":"2023-08-21T23:59:59+00:00","items":["5.07","8.01","9.01"],"status":"ready","headline":"IGC Pharma shareholders pass all five proposals at 2023 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Claudia Grimaldi elected Class A director with 14.7M for, 1.4M withheld, 11M broker non-votes.","Ratified Manohar Chowdhry & Associates as auditor for FY2024: 26.9M for, 163K against.","Approved grant of 3M common shares to employees, advisors, directors; 14.3M for.","Say-on-pay approved (15.3M for); frequency set at every three years (13.1M for 3 yrs).","Board adopts triennial advisory vote on executive compensation going forward."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":28285807.226896554,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":275965,"accession_number":"0001185185-23-000691","cik":1326205,"company_name":"IGC Pharma, Inc.","ticker":"IGC","form_type":"8-K","filed_at":"2023-07-07T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"IGC Pharma secures $12M revolving credit from O-Bank for Alzheimer's research","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Up to $12M revolving credit facility; initial 12-month term with possible extension.","Draws limited to $1M per 30-day period; interest rate is 1% plus certificate of deposit rate.","Bradbury Asset Management has collateralized cash assets supporting the line; Bradbury recently invested $3M in IGC.","Proceeds support working capital, primarily for Phase 2 trial of IGC-AD1 for Alzheimer's agitation.","Phase 2 trial targets 146 patients; 16 completed; 8 sites secured; targeting completion in Q1 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":28285807.226896554,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":275964,"accession_number":"0001185185-23-000688","cik":1326205,"company_name":"IGC Pharma, Inc.","ticker":"IGC","form_type":"8-K","filed_at":"2023-07-07T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"IGC Pharma raises $3M in private placement of 10M shares at $0.30/sh","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of $3M from Bradbury Asset Management (≈$2B AUM) and three other investors.","10 million unregistered common shares at $0.30 each; no warrants or derivatives included.","Funds to advance Phase-2 clinical trial of IGC-AD1 for agitation in Alzheimer's dementia.","Closing subject to NYSE approval; strengthens working capital for pipeline development."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":28285807.226896554,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":293595,"accession_number":"0001185185-23-000448","cik":1326205,"company_name":"IGC Pharma, Inc.","ticker":"IGC","form_type":"8-K","filed_at":"2023-05-08T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"IGC Pharma enters 5-year employment agreement with PFO Claudia Grimaldi; $200k base salary","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Five-year initial term with auto-renew; $200,000 annual base salary, subject to annual Board review.","Eligible for annual bonus and equity grants under 2018 Omnibus Incentive Plan.","Severance: if terminated without cause or for good reason, receives either base pay for remainder of term or 1.5x avg total compensation of prior 2 years; plus health and D&O coverage.","In change-of-control scenario within 12 months, severance multiplier rises to 2.99x and all unvested equity vests immediately.","Executive receives auto allowance ($95/month personal use), 20 days vacation, 8 days sick leave, and indemnification."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":28285807.226896554,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":314224,"accession_number":"0001185185-23-000238","cik":1326205,"company_name":"IGC Pharma, Inc.","ticker":"IGC","form_type":"8-K","filed_at":"2023-03-21T23:59:59+00:00","items":["5.03","7.01","9.01"],"status":"ready","headline":"India Globalization Capital rebrands as IGC Pharma, effective March 30, 2023","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Name change to IGC Pharma, Inc. effective March 30, 2023; ticker symbol IGC unchanged.","Company highlights focus on THC-based drug IGC-AD1 in Phase 2 trials for Alzheimer's agitation.","IGC-AD1 is the only natural, THC-based investigational drug in FDA trials for Alzheimer's.","Wellness brand Holief targets premenstrual syndrome, menstrual cramps, and sleep disorders.","CEO Ram Mukunda states rebranding aligns name with strategic pharma focus."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":28285807.226896554,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":332656,"accession_number":"0001185185-22-001458","cik":1326205,"company_name":"IGC Pharma, Inc.","ticker":"IGC","form_type":"8-K","filed_at":"2022-12-29T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Director John E. Lynch passes away; Jim Moran appointed to Audit and Compensation Committees","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["John E. Lynch, director since Jan 11, 2021, passed away on Dec 24, 2022.","Former Congressman Jim Moran (director since Jan 18, 2022) appointed to Audit and Compensation Committees effective Dec 27.","Richard Prins remains Chairman of Board, Audit and Compensation Committees, and Audit financial expert.","Board continues with three independent directors: Prins, Moran, and one unnamed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":28285807.226896554,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":332655,"accession_number":"0001185185-22-001432","cik":1326205,"company_name":"IGC Pharma, Inc.","ticker":"IGC","form_type":"8-K","filed_at":"2022-12-20T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"IGC posts updated life sciences presentation on website; no financial or clinical updates","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Presentation covers low-dose THC drug formulation and disease treatment initiatives.","Also highlights cannabinoid consumer product lines including Holief and Sunday Seltzer.","No new clinical trial results, partnerships, or revenue guidance disclosed.","Presentation available at igcpharma.com and filed as Exhibit 99.1."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.05,"calibrated_materiality_score":0.05,"market_cap_usd":28285807.226896554,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":350115,"accession_number":"0001185185-22-001082","cik":1326205,"company_name":"IGC Pharma, Inc.","ticker":"IGC","form_type":"8-K","filed_at":"2022-09-09T23:59:59+00:00","items":["5.02","5.07","8.01","9.01"],"status":"ready","headline":"IGC shareholders elect directors, ratify auditor, approve 3M share grant","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Ram Mukunda, James Moran elected Class C directors until 2025; Claudia Grimaldi elected Class A director until 2023.","Ratified Manohar Chowdhry & Associates as independent auditor for fiscal 2023.","Approved grant of 3,000,000 common shares to employees, advisors, directors under performance/vesting metrics.","Total shares voted: 35,103,116 (67.40% of outstanding); broker non-votes 11,861,428."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":28285807.226896554,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":367245,"accession_number":"0001185185-22-000734","cik":1326205,"company_name":"IGC Pharma, Inc.","ticker":"IGC","form_type":"8-K","filed_at":"2022-06-09T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"IGC receives U.S. patent (#11,351,152) for CBD-based seizure disorder treatment","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Patent covers compositions combining CBD with other compounds to treat seizure disorders and epilepsy in humans and animals.","Aims to reduce side effects of hydantoin anticonvulsants like phenobarbital by lowering dosing.","Company plans to pursue veterinarian pathway with observational studies and clinical trials for dogs and cats.","Approximately 50 million people worldwide affected by epilepsy; ~3.8 million dogs in U.S. suffer from seizures."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":28285807.226896554,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":367244,"accession_number":"0001185185-22-000608","cik":1326205,"company_name":"IGC Pharma, Inc.","ticker":"IGC","form_type":"8-K","filed_at":"2022-05-12T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"IGC subsidiary licenses NMI compounds from JNCASR for Alzheimer's treatment","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["Hamsa Biopharma (IGC subsidiary) obtains exclusive worldwide license for NMI Compounds from JNCASR.","NMI Compounds are small molecule inhibitors that may reduce amyloid neurotoxicity, targeting Alzheimer's and other CNS disorders.","License fee of INR [***] with milestone payment upon FDA Phase II approval; royalties of [***]% of Net Revenue.","IGC gains rights to prosecute patents, use all licensor technology, and first refusal on future CNS inventions.","Agreement includes sublicensing rights and term until last patent expiration."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":28285807.226896554,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":367243,"accession_number":"0001185185-22-000461","cik":1326205,"company_name":"IGC Pharma, Inc.","ticker":"IGC","form_type":"8-K","filed_at":"2022-04-18T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"IGC obtains final court approval of shareholder class action settlement; lawsuits dismissed","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Court granted final approval of settlement on April 13, 2022, dismissing Tchatchou and Harris-Carr consolidated class actions.","Settlement resolves all shareholder class action lawsuits pending against IGC and its officers.","Most settlement costs paid through company's insurance policy; terms previously disclosed in Form 10-Q filed Feb 10, 2022.","IGC continues Alzheimer's drug development with IGC-AD1, a THC-based investigational drug; Phase 2 trial planned."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":28285807.226896554,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":386614,"accession_number":"0001185185-22-000312","cik":1326205,"company_name":"IGC Pharma, Inc.","ticker":"IGC","form_type":"8-K","filed_at":"2022-03-23T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"IGC appoints Claudia Grimaldi to Board as non-independent director","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Claudia Grimaldi appointed to the Board as non-independent director, effective March 23, 2022.","Board now has 5 directors, majority independent; Grimaldi currently VP, Principal Finance Officer, and CCO.","Grimaldi's employment agreement provides $150K base salary, benefits, and 18-month severance on termination without cause.","She also serves as Managing Director of Hamsa Biochem SAS (Colombia subsidiary) and director of India subsidiary."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":28285807.226896554,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":386613,"accession_number":"0001185185-22-000067","cik":1326205,"company_name":"IGC Pharma, Inc.","ticker":"IGC","form_type":"8-K","filed_at":"2022-01-18T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"India Globalization Capital appoints former Congressman Jim Moran to board of directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Appointed former Congressman Jim Moran as independent Class C director effective Jan 18, 2022.","Moran served Virginia's 8th District for 24 years; was on Appropriations, Banking, and Budget committees.","He received 150,000 RSUs: 50,000 vest immediately, remainder over 2 years.","Press release highlights Moran's expertise and IGC's Phase 2/3 Alzheimer's trial for IGC-AD1."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":28285807.226896554,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":404548,"accession_number":"0001185185-21-001785","cik":1326205,"company_name":"IGC Pharma, Inc.","ticker":"IGC","form_type":"8-K","filed_at":"2021-12-02T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"IGC Phase 1 trial for THC-based Alzheimer's drug IGC-AD1 shows statistically significant NPI reductions; no SAEs","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Mean NPI decreased from baseline 31.5 to 16.7 on day 10 (p=0.0044) in Cohort 1; improvements in agitation, anxiety, appetite disorders.","No serious adverse events or deaths across all cohorts; only one related AE (mild dizziness) reported.","IGC plans to design a larger multi-site Phase 2/3 trial pending FDA approval for IGC-AD1.","Sixty-two percent of participants had CYP2C9 intermediate metabolizer phenotype, affecting THC half-life (5.09 h vs 1.73 h for normal)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":28285807.226896554,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":404547,"accession_number":"0001185185-21-001711","cik":1326205,"company_name":"IGC Pharma, Inc.","ticker":"IGC","form_type":"8-K","filed_at":"2021-11-19T23:59:59+00:00","items":["1.01","5.02","9.01"],"status":"ready","headline":"IGC enters 5-year CEO employment agreement with Ram Mukunda; salary $360K","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Employment agreement effective November 18, 2021; initial 5-year term with automatic 12-month renewals.","Annual base salary of $360,000; eligible for annual bonus and equity grants under 2018 Omnibus Incentive Plan.","Severance: 1.5x avg total comp (non-CIC) paid over 18 months; 2.99x lump sum upon change-in-control.","Post-termination non-compete for 12 months; must retain 35% of equity received during tenure.","Perquisites include car allowance ($1,500/month lease), D&O insurance for 10 years post-termination."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":28285807.226896554,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":404546,"accession_number":"0001185185-21-001484","cik":1326205,"company_name":"IGC Pharma, Inc.","ticker":"IGC","form_type":"8-K","filed_at":"2021-10-15T23:59:59+00:00","items":["5.02","5.07","8.01","9.01"],"status":"ready","headline":"IGC shareholders approve director election, ratify auditor, and authorize 3.5M share equity grant","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Richard Prins elected as Class B director, term through 2024 annual meeting.","Manohar Chowdhry & Associates ratified as independent auditor for fiscal 2022.","Board authorized grant of up to 3,500,000 common shares to employees, advisors, directors, and consultants.","Meeting turnout: 37,257,143 shares voted (≈73% of outstanding); 21,876,265 broker non-votes.","All four proposals passed; adjournment proposal was unnecessary."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":28285807.226896554,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}